Journal special edition outlines rotavirus burden and need for vaccines

November 05, 2009

Seattle, WA--The Journal of Infectious Diseases has released a special edition, Global Rotavirus Surveillance: Preparing for the Introduction of Rotavirus Vaccines. This special edition provides a significant contribution to the understanding of rotavirus disease burden and the impact of rotavirus vaccines, which have the potential to save an estimated 228,000 lives annually.

As the leading cause of severe diarrheal disease, rotavirus exacts a tremendous toll on health systems, particularly in the world's poorest countries. In addition to compiling data on rotavirus incidence from around the globe, this collection of scientific articles also covers strain diversity, the need for continued disease surveillance, and vaccine cost-effectiveness. The release of these pivotal data comes on the heels of the World Health Organization's (WHO) June 2009 recommendation that vaccines preventing rotavirus--the most common and lethal form of diarrheal disease--be included in every country's national immunization program.

Rotavirus is responsible for the death of more than half a million children under age 5 annually and causes approximately 40 percent of diarrhea-related hospitalizations. Nearly every child in the world, regardless of socio-economic status or geographic location, will contract rotavirus by age 3. However, its burden is disproportionally felt in developing countries in Africa and Asia, where rotavirus is often fatal because children cannot access emergency care.

"Rotavirus is one of the most deadly diseases children in the developing world face," said Dr. John Wecker, director of the Vaccine Access and Delivery Global Program at PATH. "Vaccination holds the key to making it one of the most preventable diseases."

Regional surveillance networks have generated rotavirus disease and strain burden data in nearly 60 countries since 2001, demonstrating tremendous burden and supporting the need for widespread rotavirus vaccine use. The WHO has advocated for the global introduction of rotavirus vaccines as a key component of the strategy to reduce child deaths from diarrheal disease--the second leading killer of children today.

"As these articles demonstrate, the burden of rotavirus is felt worldwide," said Marc-Alain Widdowson, epidemiologist at the U.S. Centers for Disease Control and Prevention and lead author of the introductory article in the special edition. "The global health community must work together with public and private sector partners to help every country use available interventions--including vaccines--to stop child diarrheal disease deaths."

Vaccines preventing rotavirus have been licensed in more than 100 countries, many of which are in the industrialized world, and their routine use is dramatically reducing severe infections. The vaccines have not yet reached many of the places where the rotavirus burden is greatest--especially in the developing countries of Africa and Asia.

"Vaccines are the best way to prevent rotavirus-related hospitalizations in industrialized countries and to avoid unnecessary child deaths in places where access to medical care and lifesaving interventions may be limited," said Dr. Duncan Steele, senior technical advisor for PATH's Vaccine Development Global Program and co-author of the introductory article in the special edition. Steele started his work on the article while at the WHO's Initiative for Vaccine Research.

Today, two orally administered vaccines preventing rotavirus, RotarixTM--produced by GlaxoSmithKline Biologicals, and RotaTeq®, produced by Merck--are available, and new vaccines are in development. The WHO recommendation on global use of these vaccines was based on large-scale clinical trials demonstrating vaccine efficacy in impoverished, high-mortality settings. It builds on a 2006 recommendation to include rotavirus vaccines in the national immunization programs of countries in Europe, Latin America, and North America. Informed by the WHO decision, the GAVI Alliance has committed to providing eligible countries with financial support for rotavirus vaccine introduction and is currently accepting applications.
-end-
To access the Journal of Infectious Diseases supplement Global Rotavirus Surveillance: Preparing for the Introduction of Rotavirus Vaccines, please visit: http://www.journals.uchicago.edu/toc/jid/200/s1.PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH's work improves global health and well-being. For more information, please visit www.path.org.

PATH

Related Infectious Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Forecasting elections with a model of infectious diseases
Election forecasting is an innately challenging endeavor, with results that can be difficult to interpret and may leave many questions unanswered after close races unfold.

COVID-19 a reminder of the challenge of emerging infectious diseases
The emergence and rapid increase in cases of coronavirus disease 2019 (COVID-19), a respiratory illness caused by a novel coronavirus, pose complex challenges to the global public health, research and medical communities, write federal scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and from the Centers for Disease Control and Prevention (CDC).

Certain antidepressants could provide treatment for multiple infectious diseases
Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.

Opioid epidemic is increasing rates of some infectious diseases
The US faces a public health crisis as the opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections.

Infectious diseases could be diagnosed with smartphones in sub-Saharan Africa
A new Imperial-led review has outlined how health workers could use existing phones to predict and curb the spread of infectious diseases.

The Lancet Infectious Diseases: Experts warn of a surge in vector-borne diseases as humanitarian crisis in Venezuela worsens
The ongoing humanitarian crisis in Venezuela is accelerating the re-emergence of vector-borne diseases such as malaria, Chagas disease, dengue, and Zika virus, and threatens to jeopardize public health gains in the country over the past two decades, warn leading public health experts.

Glow-in-the-dark paper as a rapid test for infectious diseases
Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) present a practicable and reliable way to test for infectious diseases.

Math shows how human behavior spreads infectious diseases
Mathematics can help public health workers better understand and influence human behaviors that lead to the spread of infectious disease, according to a study from the University of Waterloo.

Many Americans say infectious and emerging diseases in other countries will threaten the US
An overwhelming majority of Americans (95%) think infectious and emerging diseases facing other countries will pose a 'major' or 'minor' threat to the U.S. in the next few years, but more than half (61%) say they are confident the federal government can prevent a major infectious disease outbreak in the US, according to a new national public opinion survey commissioned by Research!America and the American Society for Microbiology.

Read More: Infectious Diseases News and Infectious Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.